Drug Profile


Alternative Names: CTN SR; EB-1020; EB-1020 SR

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Euthymics Bioscience
  • Developer Euthymics Bioscience; Neurovance
  • Class Azabicyclo compounds; Cyclohexanes; Naphthalenes; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder
  • No development reported Major depressive disorder; Neuropathic pain

Most Recent Events

  • 01 Nov 2017 Ethismos Research acquires intellectual property assets of centanafadine from Euthymics Bioscience
  • 20 Dec 2016 Neurovance plans a phase III trial for Attention-deficit hyperactivity disorder
  • 27 Jul 2016 Efficacy data from a phase IIb trial in Attention-deficit hyperactivity disorder released by Neurovance
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top